A 61-year-old female with NSCLC harboring EGFR mutation and both EGFR and MET gene amplification with progressive disease after treatment with osimertinib was enrolled in the 1719-001 clinical trial. NGS demonstrated homozygous MTAP deletion….The patient was administered MRTX1719 at 400 mg q.d. p.o. on a 21-day cycle and tolerated the treatment well. The first on-study disease assessment at cycle 2 day 20 demonstrated a RECIST-defined partial response with a 41% reduction of the target lesion and was confirmed at cycle 5 day 1 (Fig. 6). The patient remains on study treatment through cycle 6.